Real-world Data

This site is intended only for healthcare professionals resident in Egypt

Log Out

Our medicines

Therapy areas

Explore content

Events

Downloadable materials

Videos

Let’s connect

Ask a question

Pfizer medical information

Clinical Information

Stroke Prevention in Atrial Fibrillation

Morbidity and Mortality

Efficacy

Aristophanes

Safety

Real-world Data

Guideline recommendations

Persistence and Adherence

Dosing

Summary

Venous Thromboembolism Treatment

Efficacy

Safety

Real-world Data

Guideline recommendations

Dosing

Venous Thromboembolism Prevention

Efficacy

Safety

Dosing

Eliquis Important Safety Information

Eliquis Abbreviated Prescribing Information (2.5 mg)

Eliquis Abbreviated Prescribing Information (5 mg)

Support & Services

Support & Services

Self-detail presentations

Webinars

Materials

Videos

Overview of Real-World Data

Real-world settings study demonstrated a significantly higher risk of hospitalization (all-cause, stroke/SE, and major bleeding) associated with warfarin, a significantly higher risk of major bleeding hospitalization associated with dabigatran or rivaroxaban, and a significantly higher risk of all-cause hospitalization associated with rivaroxaban compared to apixaban. Lower major bleeding-related costs were observed for apixaban patients compared to warfarin and rivaroxaban patients.³

Eliquis® was associated with a lower risk of major bleeding (hazard ratio = 0.44 [95% CI: 0.12–0.97]) compared with VKA.⁴

Evidence of the safety of NOAC use in the real-world setting and may facilitate clinical decision making, especially in Italy where data on the real-world use of NOACs have been lacking.⁴

*Study lives indicate the number of patient records examined; while known duplicate records have been removed, these may not represent discrete patient lives. Numbers are accurate as of January 2020.

†Based on transferability of trial findings to clinical practice

NOAC: non-vitamin K antagonist oral anticoagulant; US: United States

References: 1. ELIQUIS ® 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8:699-708. 3. Amin A, Keshishian A, Vo L, et al. Real-world comparison of all- cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. J Med Econ. 2018;21(3:244-253. 4. Ramagopalan S, Allan V, Saragoni S, et al. Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases. J Comp Eff Res. 2018;7(11:1063-1071. 5. Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018;49(12:2933-2944. 6. Kohsaka S, Murata T, Izumi N, Katada J, Wang F, Terayama Y. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. Curr Med Res Opin. 2017;33(11:1955-1963. 7. Amin A, Keshishian A, Trocio J, et al. Risk of stroke/ systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33(9):1595- 1604. 8. Lamberts M, Staerk L, Olesen JB, et al. Major Bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life danish patients. J Am Heart Assoc. 2017;6(2). pii:e004517. 9. Lip GY, Pan X, Kamble S, et al. Major bleeding risk among nonvalvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States. Int J Clin Pract. 2016;70(9):752-763. 10. Xie L, Vo L, Keshishian A, et al. Comparison of hospital length of stay and hospitalization costs among patients with nonvalvular atrial fibrillation treated with apixaban or warfarin: An early view. J Med Econ. 2016;19(8):769-776. 11. Hohnloser SH, Basic E, Hohmann C, Nabauer M. Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation. Thromb Haemost. 2018;118(3):526-538.

Explore more

VTE treatment Dosing

Learn more

Click here for Eliquis® 2.5mg Prescribing Information Click here for Eliquis® 5mg Prescribing Information	HF0098OA455/122022 Invalidation Date : 21/08/2024

PP-ELI-EGY-0467

Quick Links

SPAF Guideline recommendations

Learn more

SPAF Aristophanes

Learn more

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Account

Sign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries.

PP-UNP-EGY-0241

You are leaving the Pfizer for Professionals website

You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.

PP-UNP-EGY-0241

You are leaving the Pfizer for Professionals website